Kindred Biosciences (KIN) stock price, revenue, and financials

Kindred Biosciences market cap is $183.1 m, and annual revenue was $4.26 m in FY 2019

$183.1 M

KIN Mkt cap, 23-Sept-2020

$163 K

Kindred Biosciences Revenue Q2, 2020
Kindred Biosciences Gross profit (Q2, 2020)136 K
Kindred Biosciences Gross profit margin (Q2, 2020), %83.4%
Kindred Biosciences Cash, 30-Jun-202026.9 M
Kindred Biosciences EV179 M

Kindred Biosciences Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.0m4.3m

Cost of goods sold

324.0k587.0k

Gross profit

1.6m3.7m

Gross profit Margin, %

84%86%

R&D expense

18.7m19.4m13.9m17.7m26.4m28.3m

General and administrative expense

8.5m7.9m8.3m14.0m26.5m37.9m

Operating expense total

27.2m27.3m22.8m31.7m52.9m66.2m

EBIT

(27.2m)(27.3m)(22.8m)(31.7m)(51.3m)(62.6m)

EBIT margin, %

(2607%)(1470%)

Interest income

325.0k774.0k1.6m1.2m

Investment income

94.0k132.0k

Net Income

(27.1m)(27.1m)(22.5m)(30.9m)(49.7m)(61.4m)

Kindred Biosciences Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.0m20.0m6.7m34.8m56.3m16.0m

Accounts Receivable

903.0k923.0k

Prepaid Expenses

797.0k1.7m2.5m

Inventories

1.9m1.8m3.6m4.2m

Current Assets

101.5m73.8m58.0m81.8m80.1m79.3m

PP&E

394.0k1.2m2.4m7.5m26.3m29.8m

Total Assets

101.9m79.6m61.6m90.8m106.5m114.0m

Accounts Payable

420.0k717.0k410.0k1.4m3.6m1.3m

Short-term debt

644.0k

Current Liabilities

2.9m3.2m3.9m6.0m15.2m10.2m

Long-term debt

21.9m

Non-Current Liabilities

115.0k94.0k

Total Debt

22.5m

Total Liabilities

3.9m6.1m15.3m32.1m

Common Stock

3.0k3.0k4.0k

Additional Paid-in Capital

130.5m135.0m138.8m196.7m252.9m305.0m

Retained Earnings

(31.5m)(58.6m)(81.1m)(112.0m)(161.7m)(223.1m)

Total Equity

76.4m57.7m84.7m91.2m81.9m

Financial Leverage

1 x1.1 x1.1 x1.2 x1.4 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

36.5m9.3m8.3m5.4m14.8m4.5m9.6m16.0m13.3m19.9m36.9m43.6m44.5m85.4m70.0m68.6m32.0m39.2m14.0m26.9m

Accounts Receivable

2.1m492.0k242.0k275.0k937.0k801.0k244.0k263.0k

Prepaid Expenses

565.0k532.0k688.0k591.0k443.0k449.0k862.0k899.0k887.0k1.2m1.2m911.0k1.4m1.5m1.5m1.9m1.9m1.5m3.9m5.0m

Inventories

2.5m4.5m4.4m4.2m824.0k389.0k

Current Assets

61.1m113.0m107.1m95.2m90.2m84.0m69.4m62.1m61.4m68.4m75.3m87.2m72.2m111.5m95.9m102.7m86.7m94.0m58.4m72.8m

PP&E

27.0k109.0k194.0k391.0k397.0k608.0k1.7m1.7m1.8m2.6m2.6m6.4m7.9m10.6m17.5m28.1m28.6m29.6m30.3m29.6m

Total Assets

61.1m113.1m107.3m95.6m90.6m84.7m73.1m68.9m65.2m74.0m78.9m96.7m80.2m122.1m113.4m132.7m117.1m125.3m92.7m115.9m

Accounts Payable

1.7m1.7m744.0k347.0k1.1m285.0k567.0k229.0k690.0k994.0k301.0k398.0k700.0k528.0k1.2m1.2m643.0k1.4m2.8m639.0k

Short-term debt

618.0k657.0k

Current Liabilities

2.4m2.2m2.8m3.0m1.9m1.7m2.6m2.8m2.5m3.6m3.9m6.3m8.9m11.3m7.6m10.1m10.2m6.9m

Long-term debt

1.1m991.0k804.0k21.9m22.2m

Non-Current Liabilities

44.0k41.0k37.0k46.0k33.0k26.0k18.0k61.0k87.0k90.0k111.0k107.0k99.0k

Total Debt

1.1m991.0k804.0k22.5m22.8m

Total Liabilities

2.6m3.4m2.4m2.2m2.9m3.0m1.9m1.7m2.7m2.9m2.6m3.7m4.0m6.4m9.0m12.4m8.6m30.1m32.1m29.1m

Common Stock

2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k3.0k3.0k3.0k3.0k4.0k4.0k4.0k4.0k4.0k

Additional Paid-in Capital

69.0m128.3m129.6m131.6m132.8m133.8m135.8m136.8m137.8m158.8m170.7m195.2m198.1m249.0m250.7m298.0m300.5m302.5m306.5m308.5m

Retained Earnings

(10.5m)(18.6m)(24.7m)(38.2m)(45.1m)(52.2m)(64.7m)(69.6m)(75.3m)(87.6m)(94.4m)(102.2m)(122.0m)(133.2m)(146.2m)(177.7m)(192.0m)(207.3m)(245.8m)(221.8m)

Total Equity

58.5m109.7m104.9m93.4m87.7m81.7m71.1m67.2m62.5m71.1m76.3m92.9m76.2m115.8m104.4m120.3m108.4m95.2m60.7m86.8m

Financial Leverage

1 x1 x1 x1 x1 x1 x1 x1 x1 x1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.3 x1.5 x1.3 x

Kindred Biosciences Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(120.0k)(27.1m)(5.8m)(30.9m)(49.7m)(61.4m)

Depreciation and Amortization

146.0k155.0k475.0k805.0k2.5m

Accounts Receivable

(903.0k)(20.0k)

Inventories

(14.1m)16.0m(37.9m)(3.6m)(648.0k)

Accounts Payable

6.0k30.0k(710.0k)1.3m277.0k1.8m

Cash From Operating Activities

(62.0k)(22.8m)(18.8m)(21.9m)(45.0m)(56.3m)

Purchases of PP&E

(729.0k)(952.0k)(5.9m)(13.9m)(8.4m)

Cash From Investing Activities

29.4m5.3m(2.7m)16.6m(47.8m)

Cash From Financing Activities

1.0m343.0k162.0k52.7m49.9m63.8m

Net Change in Cash

28.1m21.5m(40.3m)

Kindred Biosciences Ratios

USDQ1, 2014

Financial Leverage

1 x

Kindred Biosciences Employee Rating

3.18 votes
Culture & Values
3
Work/Life Balance
2.6
Senior Management
3.1
Salary & Benefits
3
Career Opportunities
3.2
Source